Clinical outcomes of weekly adalimumab in refractory non-infectious paediatric uveitis and the role of serum drug levels and anti-adalimumab antibodies.

Adalimumab (adalimumab) is a well-established treatment for refractory paediatric uveitis; however, some patients remain inadequately controlled on standard biweekly dosing.

This study evaluates outcomes of escalation to weekly adalimumab in children with refractory uveitis and explores the relevance of serum drug levels and anti-adalimumab antibodies (anti-ADA antibodies).